Humacyte shares tanked over 20% to a record low after the company priced a $20 million stock offering at a 25% discount. Despite securing a $1.5 million order from Saudi Arabia for its Symvess blood vessel and discussing a potential JV, the dilutive capital raise weighed heavily on investor sentiment.